Last reviewed · How we verify
Mercilon
At a glance
| Generic name | Mercilon |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers (PHASE3)
- Comparative Trial in Hormone Withdrawal Associated Symptoms (PHASE3)
- Contraceptive Pill and Hormonal Vaginal Ring in Women With Polycystic Ovary Syndrome (PHASE4)
- Premenstrual Symptoms Treatment Comparing Between Oral Contraceptives Containing Desogestrel and Drospirenone (PHASE4)
- The Effect of Hormonal Contraceptives on Androgens and Glucose Metabolism (NA)
- A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon. (PHASE3)
- Efficacy Study of Atorvastatin in Pelvic Pain Relief in Women With Endometriosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mercilon CI brief — competitive landscape report
- Mercilon updates RSS · CI watch RSS
- Bayer portfolio CI